Cassava Sciences' Alzheimer's drug trials disappointed, leading to early study discontinuations. Check out why I rate SAVA ...

Cassava Sciences' Phase 3 trial for Alzheimer's failed to meet primary or secondary endpoints, leading to the discontinuation ...

NEW YORK, NY / ACCESSWIRE / December 2, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cassava ...

NEW YORK, NY / ACCESSWIRE / November 29, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cassava ...

Cassava Sciences, Inc. (NASDAQ:SAVA – Free Report) – Research analysts at HC Wainwright decreased their FY2024 earnings estimates for shares of Cassava Sciences in a research report issued on ...

On Tuesday, Cassava Sciences Inc (SAVA) stock saw a decline, ending the day at $3.83 which represents a decrease of $-0.47 or -10.93% from the prior close of $4.3. The stock opened at $4.32 and ...

Pomerantz LLP is investigating claims on behalf of investors of Cassava Sciences, Inc. ("Cassava" or the "Company") . Such investors are advised to contact Danielle Peyton at [email protected] or ...

Cassava Sciences Inc’s profitability metrics reveal financial health. The company currently boasts an operating margin of 0.00% with a gross margin of -82.27%. The profit margin, also known as the ...

Cassava Sciences’ ReThink-ALZ phase 3 study of simufilam in mild-to-moderate AD fails to meet co-primary endpoints: Austin, Texas Wednesday, November 27, 2024, 18:00 Hrs [IST] C ...

Cassava Sciences' troubled development of Alzheimer's disease candidate simufilam looks like it may have finally reached the end. The Austin, Texas-based biotech revealed that simufilam failed its ...